Cowen Starts Ocata (OCAT) at Outperform

Cowen initiates coverage on Ocata (NASDAQ: OCAT) with a Outperform rating.

Analyst Boris Peaker commented, "We are initiating coverage of Ocata with an Outperform rating. OCAT is developing a stem cell therapy platform for the treatment of retinal disorders. Its products have the potential to delay/rescue visual loss in diseases where there are currently no approved therapies. As additional safety/efficacy data are reported and pivotal trials initiated, we expect significant appreciation of OCAT shares."

For an analyst ratings summary and ratings history on Ocata click here. For more ratings news on Ocata click here.

Shares of Ocata closed at $5.08 yesterday.

You May Also Be Interested In

• Macquarie Downgrades Roblox Corp. (RBLX) to Neutral
• Illumina (ILMN) PT Raised to $225 at Stifel
• TD Cowen on DexCom (DXCM): 'Outperformance from Top to Bottom-line'